e-learning
resources
Copenhagen 2005
Monday 19.09.2005
COPD - treatment II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of long-term treatment with erdosteine on moderate or severe COPD patients
M. Moretti, R. Assereto (Modena, Milan, Italy)
Source:
Annual Congress 2005 - COPD - treatment II
Session:
COPD - treatment II
Session type:
Thematic Poster Session
Number:
1948
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Moretti, R. Assereto (Modena, Milan, Italy). The effect of long-term treatment with erdosteine on moderate or severe COPD patients. Eur Respir J 2005; 26: Suppl. 49, 1948
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Effect of erdosteine in moderately severe COPD patients
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 194s
Year: 2007
The effect of tiotropium in the treatment of patients with COPD
Source: Annual Congress 2010 - COPD: management
Year: 2010
Siccine acid effects in patients with exacerbation of severe COPD
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007
Comparison of the effect of short course of oral prednisone in patients with moderate and severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 281s
Year: 2003
Long-term use of antioxidant mucolytic erdosteine is especially beneficial in patients with more severe COPD
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Impact of moderate and severe exacerbations in severe COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Effects of exercise in patients with moderate to severe asthma
Source: Annual Congress 2008 - Risk factors for asthma versus asthma control
Year: 2008
The efficacy and side-effects of varenicline in patients with mild to moderate chronic obstructive pulmonary diseases
Source: Annual Congress 2010 - Passive smoking
Year: 2010
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Short-term effects of pulmonary rehabilitation on asthma control in patients with moderate-severe unstable asthma
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019
Salmeterol/fluticasone therapy improves FEV
1
in mild and moderate more than in severe COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
Source: Eur Respir J 2014; 44: 527-529
Year: 2014
Effect of roflumilast in patients with severe COPD and a history of hospitalisation
Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017
Year: 2017
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 379s
Year: 2004
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept